Filing Details

Accession Number:
0001415889-12-001792
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-11-29 20:35:40
Reporting Period:
2012-11-27
Filing Date:
2012-11-29
Accepted Time:
2012-11-29 20:35:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1291969 H Thomas Aasen 3911 Sorrento Valley Blvd
San Diego CA 92121
Exec Vp, Cfo And Cbo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2012-11-27 33,631 $0.00 28,471 No 5 G Direct
Common Stock Acquisiton 2012-11-27 33,631 $0.00 35,000 No 5 G Indirect By Family Trust
Common Stock Disposition 2012-11-27 30,900 $6.24 4,100 No 4 S Indirect By Family Trust
Common Stock Acquisiton 2012-11-28 5,000 $1.08 33,471 No 4 M Direct
Common Stock Disposition 2012-11-28 5,000 $0.00 28,471 No 5 G Direct
Common Stock Acquisiton 2012-11-28 5,000 $0.00 9,100 No 5 G Indirect By Family Trust
Common Stock Disposition 2012-11-28 9,100 $5.25 0 No 4 S Indirect By Family Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 5 G Indirect By Family Trust
No 4 S Indirect By Family Trust
No 4 M Direct
No 5 G Direct
No 5 G Indirect By Family Trust
No 4 S Indirect By Family Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2012-11-28 5,000 $0.00 5,000 $1.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,510 2003-09-08 2013-09-07 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2011.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in mulitple transactions at prices ranging from $6.00 to $6.50 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.26 per share, inclusive.